How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

- Tiong, Ing Soo, Wall, Meaghan, Marlton, Paula, Johnston, Amanda, Enjeti, Anoop, Fong, Chun Yew, Cull, Gavin, Larsen, Stephen, Kennedy, Glen, Schwarer, Anthony, Kipp, David, Ramanathan, Sundra, Bajel, Ashish, Verner, Emma, Tiley, Campbell, Morris, E, Hahn, U, Moore, J, Taper, J, Purtill, D, Warburton, P, Stevenson, W, Murphy, N, Kalro, Akash, Tan, P, Beligaswatte, A, Mutsando, H, Hertzberg, M, Shortt, J, Szabo, F, Dunne, K, Wei, AH, Australasian Leukaemia and Lymphoma Group (ALLG),, Fleming, Shaun, Roberts, Andrew W., Thiagarajah, Nisha, Chua, Chong Chyn, Latimer, Maya, Yeung, David

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

- Loo, Sun, Roberts, Andrew W., Taper, John, Cull, Gavin, Tiley, Campbell, Verner, Emma, Hahn, Uwe, Hiwase, Devendra K., Iland, Harry J., Murphy, Nick, Ramanathan, Sundra, Reynolds, John, Anstee, Natasha S., Ong, DM, Tiong, IS, Wall, M, Murray, M, Rawling, T, Leadbetter, J, Rowley, L, Latimer, M, Yuen, SLS, Ting, SB, Kennedy, Glen A., Fong, CY, Morris, KL, Bajel, A, Seymour, JF, Levis, MJ, Wei, AH, He, Simon, Schwarer, Anthony P., Enjeti, Anoop K., D'Rozario, James, Marlton, Paula, Bilmon, Ian A.